Figure 5 | Scientific Reports

Figure 5

From: p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab

Figure 5

DIACC3010 and trastuzumab synergized to reduce cell growth and colony formation in OE-19 cells, but not in NCI-N87 cells. (a) Results of cell proliferation assays of DIACC3010 + trastuzumab using a Bliss independence model employing 6 × 7 dose matrices. The combination matrices were performed at least 3 times for OE-19 and NCI-N87 cell lines. Circled cells indicate scores at clinically relevant exposure of DIACC3010 and standard in vitro treatment dose of trastuzumab; (b) Visualization of colony formation assays (CFA) of cell lines with relatively low (NCI-N87) and high (OE-19) mean Bliss sums with varying levels of HER2 expression treated with DIACC3010 and trastuzumab. In agreement with the Bliss data, the only cell line exhibiting synergistic growth inhibition following treatment with the two agents was OE-19. (c) Quantitative data of CFA as mean % of control ± SD *p = 0.05. ns = not significant.

Back to article page